Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W R Shanahan

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Expert Opinion on Investigational Drugs|July 5, 2005
ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1W R Shanahan
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|January 14, 2000
Making sense of antisenseB R Yacyshyn, W R Shanahan
Arthritis and Rheumatism|December 1, 1982
Cytotoxic activity of sera from scleroderma and other connective tissue diseases. Lack of cellular and disease specificityW R Shanahan, J H Korn
Journal of Leukocyte Biology|March 1, 1985
Endothelial cells enhance the human pokeweed mitogen lymphocyte responseW R Shanahan, D M Weston, J H Korn
Journal of Experimental Pathology|January 1, 1989
Expression of IL-1 and tumor necrosis factor by endothelial cells: role in stimulating fibroblast PGE2 synthesisW R Shanahan, W W Hancock, J H Korn
Molecular Biotechnology|November 11, 1999
Preclinical and clinical pharmacology of antisense oligonucleotidesE G Marcusson, B R Yacyshyn, W R Shanahan, et al.
Clinical Immunology and Immunopathology|May 1, 1987
Allogeneic fibroblasts and endothelial cells support mitogen but not antigen responses of tetanus-responsive T-cell linesW R Shanahan, S J Padula, R B Clark, et al.
The Journal of Rheumatology|January 1, 1982
Assessment of longterm benefit of total hip replacement in patients with ankylosing spondylitisW R Shanahan, R E Kaprove, P A Major, et al.
Gastroenterology|June 3, 1998
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's diseaseB R Yacyshyn, M B Bowen-Yacyshyn, L Jewell, et al.
Gut|June 22, 2002
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's diseaseB R Yacyshyn, W Y Chey, J Goff, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Expert Opinion on Investigational Drugs|July 5, 2005
ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1W R Shanahan
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|January 14, 2000
Making sense of antisenseB R Yacyshyn, W R Shanahan
Arthritis and Rheumatism|December 1, 1982
Cytotoxic activity of sera from scleroderma and other connective tissue diseases. Lack of cellular and disease specificityW R Shanahan, J H Korn
Journal of Leukocyte Biology|March 1, 1985
Endothelial cells enhance the human pokeweed mitogen lymphocyte responseW R Shanahan, D M Weston, J H Korn
Journal of Experimental Pathology|January 1, 1989
Expression of IL-1 and tumor necrosis factor by endothelial cells: role in stimulating fibroblast PGE2 synthesisW R Shanahan, W W Hancock, J H Korn
Molecular Biotechnology|November 11, 1999
Preclinical and clinical pharmacology of antisense oligonucleotidesE G Marcusson, B R Yacyshyn, W R Shanahan, et al.
Clinical Immunology and Immunopathology|May 1, 1987
Allogeneic fibroblasts and endothelial cells support mitogen but not antigen responses of tetanus-responsive T-cell linesW R Shanahan, S J Padula, R B Clark, et al.
The Journal of Rheumatology|January 1, 1982
Assessment of longterm benefit of total hip replacement in patients with ankylosing spondylitisW R Shanahan, R E Kaprove, P A Major, et al.
Gastroenterology|June 3, 1998
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's diseaseB R Yacyshyn, M B Bowen-Yacyshyn, L Jewell, et al.
Gut|June 22, 2002
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's diseaseB R Yacyshyn, W Y Chey, J Goff, et al.
Pageof 2